BR112014030288A2 - composição farmacêutica - Google Patents
composição farmacêuticaInfo
- Publication number
- BR112014030288A2 BR112014030288A2 BR112014030288A BR112014030288A BR112014030288A2 BR 112014030288 A2 BR112014030288 A2 BR 112014030288A2 BR 112014030288 A BR112014030288 A BR 112014030288A BR 112014030288 A BR112014030288 A BR 112014030288A BR 112014030288 A2 BR112014030288 A2 BR 112014030288A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- solvate
- directed
- acceptable salt
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1 / 1 resumo. âcomposiãão farmacãuticaâ a presente invenã§ã£o ã© dirigida a uma composiã§ã£o farmacãªutica, que compreende um carreador farmaceuticamente aceitã¡vel e um composto metanossulfonilalquilnitrila, ou um sal farmaceuticamente aceitã¡vel do mesmo ou um solvato do mesmo. a presente invenã§ã£o ã© tambã©m dirigida a um mã©todo para o tratamento de inflamaã§ã£o, distãºrbios relacionados inflamatã³rios, ou dor, atravã©s da administraã§ã£o de um composto metanossulfonilalquilnitrila ou de um sal farmaceuticamente aceitã¡vel do mesmo ou um solvato do mesmo, a um paciente que esteja em necessidade do mesmo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261655891P | 2012-06-05 | 2012-06-05 | |
PCT/US2013/044149 WO2013184703A1 (en) | 2012-06-05 | 2013-06-04 | Pharmaceutical composition for treating inflammation and pain |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014030288A2 true BR112014030288A2 (pt) | 2017-06-27 |
BR112014030288A8 BR112014030288A8 (pt) | 2021-06-22 |
Family
ID=49671008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014030288A BR112014030288A8 (pt) | 2012-06-05 | 2013-06-04 | composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila |
Country Status (10)
Country | Link |
---|---|
US (4) | US20130324603A1 (pt) |
EP (1) | EP2854786B1 (pt) |
JP (1) | JP6178412B2 (pt) |
KR (1) | KR102134046B1 (pt) |
CN (1) | CN104334165B (pt) |
AU (1) | AU2013271773B2 (pt) |
BR (1) | BR112014030288A8 (pt) |
CA (1) | CA2875053C (pt) |
MX (1) | MX366309B (pt) |
WO (1) | WO2013184703A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9522878B2 (en) | 2013-10-07 | 2016-12-20 | Olatec Therapeutics Llc | 4-methylsulfonyl-2-butenenitrile and its pharmaceutical use |
CA2896038C (en) * | 2015-07-03 | 2022-08-09 | Glycobiosciences Inc. | Polymer matrix compositions comprising a high concentration of bio-fermented sodium hyaluronate and uses thereof |
EP3565540B1 (en) * | 2017-01-06 | 2023-12-06 | Olatec Therapeutics LLC | A pharmaceutical composition for use in treating cardiovascular diseases |
JP7229565B2 (ja) * | 2018-03-21 | 2023-02-28 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | メラノーマを治療するための方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3427387A (en) * | 1964-01-09 | 1969-02-11 | Norwich Pharma Co | Antibacterial composition containing 5-nitro-2-furyl-1,2,4-triazoles |
DE3041155A1 (de) | 1980-10-31 | 1982-06-09 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von 2,3-dichlor-sulfonyl-acrylnitrilen |
GB2116964B (en) | 1981-10-16 | 1985-07-17 | Abbott Lab | (1-(2-benzoxazolyl)hydrazinojalkyl nitrile derivatives |
US5175192A (en) * | 1984-03-19 | 1992-12-29 | The Rockefeller University | Inhibitors of the advanced glycosylation of proteins and methods of use therefor |
US5218001A (en) * | 1984-03-19 | 1993-06-08 | The Rockefeller University | Inhibitors of the advanced glycosylation of proteins and methods of use therefor |
EP0355049A3 (en) | 1988-08-18 | 1990-06-13 | Zeneca Limited | Heterocyclic compounds |
JPH05310565A (ja) * | 1990-04-03 | 1993-11-22 | Univ Rockefeller | 蛋白質の高度グリコシル化抑制組成物及び抑制方法 |
KR910018021A (ko) * | 1990-04-03 | 1991-11-30 | 더 록펠러 유니버시티 | 단백질의 글리코실화 진행 억제제 및 그 이용 방법 |
US5348838A (en) | 1991-07-31 | 1994-09-20 | Kabushiki Kaisha Toshiba | Photosensitive composition comprising alkali soluble binder and photoacid generator having sulfonyl group |
US6362205B2 (en) * | 1998-11-05 | 2002-03-26 | Novo Nordisk A/S | Substituted 3,3-diamino-2-propenenitriles, their preparation and use |
US6551615B1 (en) | 2001-10-18 | 2003-04-22 | M/S. Strides Arcolab Limited | Dexibuprofen-containing soft gelatin capsules and process for preparing the same |
US7423064B2 (en) * | 2004-09-24 | 2008-09-09 | Olatec Industries, Llc | Composition for treating bacterial, viral, fungal diseases, inflammation and pain |
US20060217347A1 (en) * | 2005-03-24 | 2006-09-28 | David Perry | Topical formulations of borinic acid antibiotics and their methods of use |
ES2728455T3 (es) | 2006-02-16 | 2019-10-24 | Anacor Pharmaceuticals Inc | Moléculas pequeñas que contienen boro como agentes antiinflamatorios |
WO2007103273A2 (en) * | 2006-03-03 | 2007-09-13 | Trustees Of Boston University | Thioredoxin and thioredoxin reductase inhibitors |
US20100221336A1 (en) * | 2007-02-14 | 2010-09-02 | Logical Therapeutics, Inc. | Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and a proton pump inhibitor |
ES2830024T3 (es) * | 2007-10-19 | 2021-06-02 | Novartis Ag | Composiciones y métodos para el tratamiento del edema macular |
KR101672511B1 (ko) | 2008-03-06 | 2016-11-03 | 아나코르 파마슈티칼스 인코포레이티드 | 소염제로써 붕소가 함유된 소분자 |
WO2010018814A1 (ja) | 2008-08-12 | 2010-02-18 | 宇部興産株式会社 | 非水電解液及びそれを用いたリチウム電池 |
CN102438983A (zh) * | 2009-03-18 | 2012-05-02 | 欧拉泰克工业有限责任公司 | 用于治疗炎症和疼痛的化合物 |
JP5932830B2 (ja) * | 2010-12-15 | 2016-06-08 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | 炎症及び疼痛を処置するための3‐メタンスルホニルプロピオニトリル |
CN103071020B (zh) * | 2012-12-30 | 2014-08-20 | 慧广世纪医疗技术(天津)有限公司 | 用于小儿气管-支气管炎、肺炎治疗的外敷软膏及其制法 |
-
2013
- 2013-06-04 BR BR112014030288A patent/BR112014030288A8/pt not_active Application Discontinuation
- 2013-06-04 CA CA2875053A patent/CA2875053C/en active Active
- 2013-06-04 JP JP2015516146A patent/JP6178412B2/ja active Active
- 2013-06-04 CN CN201380029730.8A patent/CN104334165B/zh active Active
- 2013-06-04 MX MX2014014814A patent/MX366309B/es active IP Right Grant
- 2013-06-04 KR KR1020147037134A patent/KR102134046B1/ko active IP Right Grant
- 2013-06-04 WO PCT/US2013/044149 patent/WO2013184703A1/en active Application Filing
- 2013-06-04 US US13/909,891 patent/US20130324603A1/en not_active Abandoned
- 2013-06-04 AU AU2013271773A patent/AU2013271773B2/en active Active
- 2013-06-04 EP EP13800483.3A patent/EP2854786B1/en active Active
-
2017
- 2017-12-11 US US15/837,283 patent/US10751316B2/en active Active
-
2020
- 2020-08-24 US US17/001,124 patent/US20210059971A1/en not_active Abandoned
-
2023
- 2023-03-17 US US18/185,935 patent/US20230372279A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2875053A1 (en) | 2013-12-12 |
AU2013271773B2 (en) | 2018-03-08 |
JP6178412B2 (ja) | 2017-08-09 |
US10751316B2 (en) | 2020-08-25 |
US20130324603A1 (en) | 2013-12-05 |
US20180353459A1 (en) | 2018-12-13 |
CA2875053C (en) | 2020-07-14 |
KR102134046B1 (ko) | 2020-07-14 |
CN104334165B (zh) | 2017-09-05 |
BR112014030288A8 (pt) | 2021-06-22 |
MX366309B (es) | 2019-07-04 |
EP2854786A4 (en) | 2015-11-11 |
MX2014014814A (es) | 2015-02-12 |
EP2854786B1 (en) | 2017-03-29 |
EP2854786A1 (en) | 2015-04-08 |
JP2015523987A (ja) | 2015-08-20 |
WO2013184703A1 (en) | 2013-12-12 |
US20230372279A1 (en) | 2023-11-23 |
CN104334165A (zh) | 2015-02-04 |
AU2013271773A1 (en) | 2015-01-22 |
US20210059971A1 (en) | 2021-03-04 |
KR20150018852A (ko) | 2015-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
BR112015011497A2 (pt) | composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
BR112015014592A2 (pt) | composto, composição farmacêutica, e, método para o tratamento de um humano | |
BR112015008759A2 (pt) | método para a profilaxia e/ou tratamento de sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, agente profilático e/ou terapêutico para sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, uso de um composto, composto, e, composição farmacêutica | |
EA201400392A1 (ru) | ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb | |
BR112015029353A2 (pt) | derivados de pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
BR112015017525A2 (pt) | peptídeo modificado, sal de um peptídeo modificado, medicamento, e, métodos para tratar ou aliviar uma doença cardiovascular e para produzir um peptídeo modificado | |
BR112013007343A2 (pt) | métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica | |
BR112015029897A2 (pt) | composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição | |
BR112013027486A2 (pt) | combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor | |
BR112014030288A2 (pt) | composição farmacêutica | |
BR112014004732A2 (pt) | composto benzotiazolona | |
BR112015001627A2 (pt) | composição farmacêutica, respectivos usos e método para diminuir a frequência de micção | |
BR112012020377A8 (pt) | utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial | |
BR112014015578A2 (pt) | composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide | |
BR112014016450A2 (pt) | composto antagonista de leucotrieno b4 | |
BR112014030287A2 (pt) | composição farmacêutica | |
BR112014011336A2 (pt) | composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele | |
BR112014030547A2 (pt) | composição farmacêutica | |
BR112015019307A2 (pt) | derivados de ácido butanoico substituído com bisfenila como inibidores de nep com eficácia in vivo melhorada |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |